Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLNR | O43193 | 16/20 | 0.68 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | WNT3A | P56704 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2767298 | 0.89 | MLNR (0.74) | MLNRWNT3A | |
| SCHEMBL13404727 | 0.89 | MLNR (0.54) | MLNRHDAC1 | |
| SCHEMBL13404686 | 0.88 | MLNR (0.67) | MLNR | |
| SCHEMBL13404719 | 0.88 | MLNR (0.67) | MLNR | |
| SCHEMBL13404733 | 0.87 | MLNR (0.71) | MLNRHDAC1 | |
| SCHEMBL13404738 | 0.87 | MLNR (0.69) | MLNR | |
| SCHEMBL2766193 | 0.85 | MLNR (0.48) | MLNRHDAC1 | |
| SCHEMBL13404772 | 0.84 | MLNR (0.48) | MLNRHDAC1 | |
| SCHEMBL3565647 | 0.83 | MLNR (0.69) | MLNR | |
| SCHEMBL13404795 | 0.83 | MLNR (0.50) | MLNRHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853218-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2014-10-07 | — | — | US | disclosed |
| US-8853218-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2014-10-07 | — | — | US | disclosed |
| US-7700599-B2 | G protein coupled receptor inhibitors (Gpr38) such as 6-[(4-fluorophenyl)oxy]-N-methyl-N-(4-{[(3S)-3-methyl-1-piperazinyl]methyl}phenyl)-3-pyridinecarboxamide for treatment of gastric stasis in an enterally fed patient | GLAXO GROUP LIMITED (GB) | 2010-04-20 | — | — | US | disclosed |
| US-7700599-B2 | G protein coupled receptor inhibitors (Gpr38) such as 6-[(4-fluorophenyl)oxy]-N-methyl-N-(4-{[(3S)-3-methyl-1-piperazinyl]methyl}phenyl)-3-pyridinecarboxamide for treatment of gastric stasis in an enterally fed patient | GLAXO GROUP LIMITED (GB) | 2010-04-20 | — | — | US | disclosed |
| US-20090192160-A1 | COMPOUNDS | GLAXO GROUP LIMITED | 2009-07-30 | — | — | US | disclosed |
| US-20090192160-A1 | COMPOUNDS | GLAXO GROUP LIMITED | 2009-07-30 | — | — | US | disclosed |
| US-20080027065-A1 | G protein coupled receptor inhibitors (Gpr38) such as 6-[(4-fluorophenyl)oxy]-N-methyl-N-(4-{[(3S)-3-methyl-1-piperazinyl]methyl}phenyl)-3-pyridinecarboxamide for treatment of gastric stasis in an enterally fed patient | GLAXO GROUP LIMITED (GB) | 2008-01-31 | — | — | US | disclosed |
| US-20080027065-A1 | G protein coupled receptor inhibitors (Gpr38) such as 6-[(4-fluorophenyl)oxy]-N-methyl-N-(4-{[(3S)-3-methyl-1-piperazinyl]methyl}phenyl)-3-pyridinecarboxamide for treatment of gastric stasis in an enterally fed patient | GLAXO GROUP LIMITED (GB) | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027065-A1 | G protein coupled receptor inhibitors (Gpr38) such as 6-[(4-fluorophenyl)oxy]-N-methyl-N-(4-{[(3S)-3-methyl-1-piperazinyl]methyl}phenyl)-3-pyridinecarboxamide for treatment of gastric stasis in an enterally fed patient | GPR68, GPR88, GPR3 | MLNR 25/4885HDAC1 1503/4885WNT3A 1330/4885 |
| US-20090192160-A1 | COMPOUNDS | GPR68, GPR88, GPBAR1 | MLNR 251/4885HDAC1 2149/4885WNT3A 2214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.